Evidence map›Paper›PMID 40799991›Full record

ReviewMaterials today. Bio2025

Nanomedicines for the treatment of genitourinary neoplasms.

Shaowen Wang, Yongzhi Li, Xiaoting Sun, Tianping Song, You Wang, Ziyue Xue, Yang Guo, Jiawei Wang, Zhijia Cui, Peijian Lu and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shaowen WangThe Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Yongzhi LiDepartment of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaoting SunSchool of Forensic Medicine, China Medical University, Shenyang, China.
Tianping SongSchool of Intelligent Medicine, China Medical University, Shenyang, China.
You WangThe First Affiliated Hospital of China Medical University, China Medical University, Shenyang, China.
Ziyue XueSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Yang GuoThe First Affiliated Hospital of China Medical University, China Medical University, Shenyang, China.
Jiawei WangSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Zhijia CuiSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Peijian LuSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Haifeng HuangSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Diqing PanThe First Affiliated Hospital of China Medical University, China Medical University, Shenyang, China.
Dali XuSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Shuailin YouCollege of Technology and Data, Yantai Nanshan University, Yantai, China.
Wei LiuDepartment of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Tianlin WangSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Huazhe YangSchool of Intelligent Medicine, China Medical University, Shenyang, China.
Yili LiuDepartment of Urology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genitourinary neoplasms, accounting for 20-25 % of all malignant tumors, are associated with high mortality rates and pose significant challenges to clinical treatment. Especially for young patients who have reproductive demands, pharmacotherapy is a promising non-surgical strategy to improve the survival rate and quality of life. However, the distinctive interface between physiological milieu complicates effective drug delivery. Nanomedicines offer distinct advantages, including mitigating clearance, enabling precise tumor targeting, and intracellular drug delivery. Unlike most reviews about the area, which focused on a specified tumor or nanomedicine, this review, for the first time, systematically summarized the application of extensively investigated nanomedicines in the entire genitourinary neoplasms, and provided the latest and most comprehensive insights. Furthermore, we proposed the shortage of therapeutic activity and challenges in nano-therapy, and highlighted the potential of innovative and functional nanomedicines as well as emerging technology.

Indexed as

Genitourinary neoplasmsNanomedicineTherapeutics

Identifiers

PMID40799991
PMCPMC12341623

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.